IE
ABCL icon

Israel Englander’s AbCellera Biologics ABCL Stock Holding History

Israel Englander’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.07M Sell
518,571
-776,003
-60% -$3.79M ﹤0.01% 3195
2026
Q1 		$4.52M Sell
1,294,574
-478,965
-27% -$1.72M ﹤0.01% 3067
2025
Q4 		$6.07M Sell
1,773,539
-656,197
-27% -$2.93M ﹤0.01% 2801
2025
Q3 		$12.2M Sell
2,429,736
-967,853
-28% -$4.27M 0.01% 2182
2025
Q2 		$11.7M Buy
3,397,589
+2,527,880
+291% +$6.29M 0.01% 2101
2025
Q1 		$1.94M Sell
869,709
-613,006
-41% -$1.76M ﹤0.01% 3810
2024
Q4 		$4.34M Buy
1,482,715
+728,828
+97% +$2.03M ﹤0.01% 2945
2024
Q3 		$1.96M Buy
753,887
+303,197
+67% +$840K ﹤0.01% 3716
2024
Q2 		$1.33M Sell
450,690
-817,328
-64% -$3.09M ﹤0.01% 3878
2024
Q1 		$5.74M Buy
1,268,018
+12,799
+1% +$65.3K ﹤0.01% 2733
2023
Q4 		$7.17M Sell
1,255,219
-266,060
-17% -$1.23M ﹤0.01% 2484
2023
Q3 		$7M Sell
1,521,279
-1,746,339
-53% -$10.6M ﹤0.01% 2394
2023
Q2 		$21.1M Buy
3,267,618
+2,060,920
+171% +$14.1M 0.01% 1339
2023
Q1 		$9.1M Buy
1,206,698
+779,150
+182% +$7.08M 0.01% 2057
2022
Q4 		$4.33M Sell
427,548
-441,756
-51% -$5.1M ﹤0.01% 2937
2022
Q3 		$8.6M Sell
869,304
-2,087,340
-71% -$22.9M 0.01% 2332
2022
Q2 		$31.5M Buy
2,956,644
+1,462,648
+98% +$12.4M 0.02% 919
2022
Q1 		$14.6M Buy
1,493,996
+797,635
+115% +$7.55M 0.01% 1722
2021
Q4 		$9.96M Sell
696,361
-151,458
-18% -$2.3M 0.01% 2148
2021
Q3 		$17M Buy
847,819
+782,162
+1,191% +$13.8M 0.01% 1471
2021
Q2 		$1.44M Buy
65,657
+41,269
+169% +$1.14M ﹤0.01% 4306
2021
Q1 		$828K Sell
24,388
-72,168
-75% -$2.87M ﹤0.01% 4389
2020
Q4 		$3.88M Buy
+96,556
New +$4.42M ﹤0.01% 2688

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Israel Englander's ABCL Position: Q2 2026 in Review

Israel Englander reduced its AbCellera Biologics (ABCL) stake by 60% in Q2 2026, selling an estimated $3.79M and leaving 518,571 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

Israel Englander first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $31.5M in Q2 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Israel Englander held 518,571 shares of AbCellera Biologics worth $4.07M as of Q2 2026.
  • Israel Englander sold 776,003 AbCellera Biologics shares in Q2 2026, an estimated $3.79M.
  • AbCellera Biologics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3195 holding.
  • Israel Englander first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • Israel Englander's AbCellera Biologics position peaked at $31.5M in Q2 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.